Editas Medicine
EDIT
49 hedge funds and large institutions have $625M invested in Editas Medicine in 2016 Q1 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$142M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$56.1M |
| 3 |
DM
Deerfield Management
New York
|
+$44.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$37.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.7M |
Top Sellers
EDIT Hedge Fund Activity: Q1 2016 in Review
49 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2016, worth a combined $625M.
Buyers outnumbered sellers: 49 funds opened new EDIT positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $142M.
- 49 institutional investors held Editas Medicine (EDIT) as of Q1 2016, up from 0 in Q4 2015.
- Funds reported $625M of Editas Medicine stock for Q1 2016.
- 49 funds opened new Editas Medicine positions in Q1 2016 and 0 closed out, a net change of +49 holders.
- The largest Editas Medicine buyer in Q1 2016 was Fidelity Investments, an estimated $142M added.
Based on aggregated 13F filings for Q1 2016.